Lv1
84 积分 2025-11-26 加入
Evolving roles of MET as a therapeutic target in NSCLC and beyond
5天前
已完结
Molecular cloning of a new transforming gene from a chemically transformed human cell line
6天前
已完结
Radiological classification, gene-mutation status, and surgical prognosis of synchronous multiple primary lung cancer
24天前
已完结
Genomic and Transcriptomic Remodeling by Neoadjuvant Chemoradiotherapy (nCRT) and the Indicative Role of Acquired INDEL Percentage for nCRT Efficacy in Esophageal Squamous Cell Carcinoma
1个月前
已完结
Evolution of genome and immunogenome in esophageal squamous cell carcinomas driven by neoadjuvant chemoradiotherapy
1个月前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
1个月前
已完结
Drug resistance in breast cancer: Mechanisms and strategies for management
1个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1个月前
已完结
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
1个月前
已完结
Response to PARP inhibitor in EGFR-tyrosine kinase inhibitor-resistant metastatic lung adenocarcinoma with germline PALB2 mutation
1个月前
已完结
皖公网安备34019202002308
